{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T13:09:21Z","timestamp":1792674561043,"version":"4.5.0"},"reference-count":27,"publisher":"Ovid Technologies (Wolters Kluwer Health)","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>\n                      Pediatric non-Hodgkin lymphoma (NHL) is the third most common childhood malignancy, but reliable prognostication remains challenging. This study aimed to evaluate the prognostic value of baseline\n                      <jats:sup>18<\/jats:sup>\n                      F-FDG PET\/CT parameters reflecting disease spread, the largest interlesion distance (Dmax), and total metabolic tumor volume (TMTV), in pediatric patients with NHL.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and Methods:<\/jats:title>\n                    <jats:p>We retrospectively enrolled 98 pediatric patients with NHL (74 males, 24 females; median age, 10.4\u00a0y; range, 0.3\u201317.9\u00a0y) who underwent FDG PET\/CT for staging between January 2008 and November 2024. TMTVs were defined using a 41% maximum standardized uptake value threshold. Distances between all lesion pairs were calculated to determine Dmax. Prognostic significance of FDG PET\/CT parameters and clinical factors for survival outcomes was evaluated using univariate analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Based on surrogate TMTV (sTMTV) and sDmax, patients were stratified into no (n = 61), 1-risk (n = 17), and 2-risk factor groups (n = 20). In the univariate analysis, advanced stage (\u2265IV), bone marrow involvement, elevated serum lactate dehydrogenase (LDH) level (&gt;500 IU\/L), sTMTV, sDmax, and the PET-based risk group were significant prognostic factors for event-free survival (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.05). For overall survival, significant factors included LDH level, sTMTV, sDmax, and the PET-based risk group (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.05). The PET-based risk stratification was also reflected in survival outcomes.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>sTMTV and sDmax derived from FDG PET\/CT are significant prognostic biomarkers in pediatric NHL. Their combination enables effective stratification of pediatric patients with NHL into distinct risk groups and may inform future risk-adapted management strategies, potentially improving survival in this population.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/rlu.0000000000006556","type":"journal-article","created":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T22:02:21Z","timestamp":1781647341000},"update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Risk Stratification in Pediatric Non-Hodgkin Lymphoma Using Maximum Tumor Dissemination and Metabolic Tumor Burden on Baseline 18F-FDG PET\/CT"],"prefix":"10.1097","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8130-6671","authenticated-orcid":false,"given":"Sang Hyun","family":"Hwang","sequence":"first","affiliation":[{"name":"Department of Nuclear Medicine, Severance Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3668-7396","authenticated-orcid":false,"given":"Won Kee","family":"Ahn","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Division of Pediatric Hematology and Oncology, Yonsei University College of Medicine"},{"name":"Department of Pediatric Hemato-Oncology, Yonsei Cancer Center, Yonsei University Health System, Seoul, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hojin","family":"Cho","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Severance Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6088-7470","authenticated-orcid":false,"given":"Hae Won","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Division of Pediatric Hematology and Oncology, Yonsei University College of Medicine"},{"name":"Department of Pediatric Hemato-Oncology, Yonsei Cancer Center, Yonsei University Health System, Seoul, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8936-1205","authenticated-orcid":false,"given":"Jung Woo","family":"Han","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Division of Pediatric Hematology and Oncology, Yonsei University College of Medicine"},{"name":"Department of Pediatric Hemato-Oncology, Yonsei Cancer Center, Yonsei University Health System, Seoul, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9832-6380","authenticated-orcid":false,"given":"Seung Min","family":"Hahn","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Division of Pediatric Hematology and Oncology, Yonsei University College of Medicine"},{"name":"Department of Pediatric Hemato-Oncology, Yonsei Cancer Center, Yonsei University Health System, Seoul, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Won Jun","family":"Kang","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Severance Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,6,17]]},"reference":[{"key":"R1-20260801","doi-asserted-by":"crossref","first-page":"2963","DOI":"10.1200\/JCO.2014.59.5827","article-title":"Non-Hodgkin lymphoma in children and adolescents: progress through effective collaboration, current knowledge, and challenges ahead","volume":"33","author":"Minard-Colin","year":"2015","journal-title":"J Clin Oncol"},{"key":"R2-20260801","doi-asserted-by":"crossref","first-page":"e945","DOI":"10.1542\/peds.2013-3926","article-title":"Cancer incidence rates and trends among children and adolescents in the United States, 2001-2009","volume":"134","author":"Siegel","year":"2014","journal-title":"Pediatrics"},{"key":"R3-20260801","doi-asserted-by":"crossref","first-page":"1618810","DOI":"10.3389\/fped.2025.1618810","article-title":"Global burden and trends of childhood non-Hodgkin lymphoma from 1990 to 2021","volume":"13","author":"Xie","year":"2025","journal-title":"Front Pediatr"},{"key":"R4-20260801","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","article-title":"The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: lymphoid neoplasms","volume":"36","author":"Alaggio","year":"2022","journal-title":"Leukemia"},{"key":"R5-20260801","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1200\/JCO.2010.33.3369","article-title":"Advanced stage, increased lactate dehydrogenase, and primary site, but not adolescent age (\u2265 15 years), are associated with an increased risk of treatment failure in children and adolescents with mature B-cell non-Hodgkin\u2019s lymphoma: results of the FAB LMB 96 study","volume":"30","author":"Cairo","year":"2012","journal-title":"J Clin Oncol"},{"key":"R6-20260801","doi-asserted-by":"crossref","first-page":"359","DOI":"10.4143\/crt.2019.219","article-title":"Clinical characteristics and treatment outcomes of pediatric patients with non-Hodgkin lymphoma in East Asia","volume":"52","author":"Suh","year":"2020","journal-title":"Cancer Res Treat"},{"key":"R7-20260801","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1007\/s00259-016-3315-7","article-title":"Combination of baseline metabolic tumour volume and early response on PET\/CT improves progression-free survival prediction in DLBCL","volume":"43","author":"Mikhaeel","year":"2016","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R8-20260801","doi-asserted-by":"crossref","first-page":"3618","DOI":"10.1200\/JCO.2016.66.9440","article-title":"Baseline metabolic tumor volume predicts outcome in high-tumor-burden follicular lymphoma: a pooled analysis of three multicenter studies","volume":"34","author":"Meignan","year":"2016","journal-title":"J Clin Oncol"},{"key":"R9-20260801","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1093\/annonc\/mdw011","article-title":"Prognostic value of baseline total metabolic tumor volume (TMTV0) measured on FDG-PET\/CT in patients with peripheral T-cell lymphoma (PTCL)","volume":"27","author":"Cottereau","year":"2016","journal-title":"Ann Oncol"},{"key":"R10-20260801","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1182\/blood-2017-07-795476","article-title":"Prognostic value of baseline metabolic tumor volume in early-stage Hodgkin lymphoma in the standard arm of the H10 trial","volume":"131","author":"Cottereau","year":"2018","journal-title":"Blood"},{"key":"R11-20260801","doi-asserted-by":"crossref","first-page":"40","DOI":"10.2967\/jnumed.119.229450","article-title":"(18)F-FDG PET dissemination features in diffuse large B-cell lymphoma are predictive of outcome","volume":"61","author":"Cottereau","year":"2020","journal-title":"J Nucl Med"},{"key":"R12-20260801","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.annonc.2020.11.019","article-title":"Risk stratification in diffuse large B-cell lymphoma using lesion dissemination and metabolic tumor burden calculated from baseline PET\/CT(\u2020)","volume":"32","author":"Cottereau","year":"2021","journal-title":"Ann Oncol"},{"key":"R13-20260801","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1002\/hon.3025","article-title":"Prognostic value of lesion dissemination in doxorubicin, bleomycin, vinblastine, and dacarbazine-treated, interimPET-negative classical Hodgkin Lymphoma patients: a radio-genomic study","volume":"40","author":"Durmo","year":"2022","journal-title":"Hematol Oncol"},{"key":"R14-20260801","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1007\/s11604-023-01398-y","article-title":"Prognostic value of 18F-FDG lesion dissemination features in patients with peripheral T-cell lymphoma (PTCL)","volume":"41","author":"Xie","year":"2023","journal-title":"Jpn J Radiol"},{"key":"R15-20260801","first-page":"83","article-title":"WHO classification of tumours of haematopoietic and lymphoid tissues in 2008: an overview","volume":"102","author":"Sabattini","year":"2010","journal-title":"Pathologica"},{"key":"R16-20260801","first-page":"332","article-title":"Classification, staging and end results of treatment of childhood non-Hodgkin\u2019s lymphomas: dissimilarities from lymphomas in adults","volume":"7","author":"Murphy","year":"1980","journal-title":"Semin Oncol"},{"key":"R17-20260801","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.2967\/jnumed.121.263501","article-title":"(18)F-FDG PET maximum-intensity projections and artificial intelligence: a win-win combination to easily measure prognostic biomarkers in DLBCL patients","volume":"63","author":"Girum","year":"2022","journal-title":"J Nucl Med"},{"key":"R18-20260801","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1097\/RLU.0000000000002927","article-title":"Prognostic value of 18F-FDG PET\/CT-metabolic parameters at baseline and interim assessment in pediatric anaplastic large cell lymphoma","volume":"45","author":"Mathew","year":"2020","journal-title":"Clin Nucl Med"},{"key":"R19-20260801","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1097\/MNM.0000000000001182","article-title":"Comparison of clinical and PET-derived prognostic factors in patients with non-Hodgkin lymphoma: a special emphasis on bone marrow involvement","volume":"41","author":"Kupik","year":"2020","journal-title":"Nucl Med Commun"},{"key":"R20-20260801","doi-asserted-by":"crossref","first-page":"837","DOI":"10.4143\/crt.2020.123","article-title":"Baseline total metabolic tumor volume and total lesion glycolysis measured on 18F-FDG PET-CT predict outcomes in T-cell lymphoblastic lymphoma","volume":"53","author":"Feng","year":"2021","journal-title":"Cancer Res Treat"},{"key":"R21-20260801","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1056\/NEJMoa1915315","article-title":"Rituximab for high-risk, mature B-cell non-Hodgkin\u2019s lymphoma in children","volume":"382","author":"Minard-Colin","year":"2020","journal-title":"N Engl J Med"},{"key":"R22-20260801","doi-asserted-by":"crossref","first-page":"810","DOI":"10.3324\/haematol.2014.121434","article-title":"Outcome of and prognostic factors for relapse in children and adolescents with mature B-cell lymphoma and leukemia treated in three consecutive prospective \u201cLymphomes Malins B\u201d protocols. A Soci\u00e9t\u00e9 Fran\u00e7aise des Cancers de l\u2019Enfant study","volume":"100","author":"Jourdain","year":"2015","journal-title":"Haematologica"},{"key":"R23-20260801","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.21873\/invivo.13761","article-title":"Pediatric B-cell non-Hodgkin lymphoma: the impact of therapy response and relapse on outcome. a single-center analysis","volume":"38","author":"Stankiewicz","year":"2024","journal-title":"In Vivo"},{"key":"R24-20260801","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.4143\/crt.2024.104","article-title":"Stratified treatment in pediatric anaplastic large cell lymphoma: result of a prospective open-label multiple-institution study","volume":"56","author":"Chen","year":"2024","journal-title":"Cancer Res Treat"},{"key":"R25-20260801","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.3390\/diagnostics11091594","article-title":"Prognostic role of minimal disseminated disease and NOTCH1\/FBXW7 mutational status in children with lymphoblastic lymphoma: the AIEOP experience","volume":"11","author":"Lovisa","year":"2021","journal-title":"Diagnostics (Basel)"},{"key":"R26-20260801","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.3324\/haematol.2019.232314","article-title":"Quantification of minimal disseminated disease by quantitative polymerase chain reaction and digital polymerase chain reaction for NPM-ALK as a prognostic factor in children with anaplastic large cell lymphoma","volume":"105","author":"Damm-Welk","year":"2020","journal-title":"Haematologica"},{"key":"R27-20260801","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.3390\/cancers13081907","article-title":"Minimal disease monitoring in pediatric non-Hodgkin\u2019s lymphoma: current clinical application and future challenges","volume":"13","author":"Mussolin","year":"2021","journal-title":"Cancers (Basel)"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/RLU.0000000000006556","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T08:00:13Z","timestamp":1785571213000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/RLU.0000000000006556"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,17]]},"references-count":27,"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000006556","relation":{},"ISSN":["0363-9762","1536-0229"],"issn-type":[{"value":"0363-9762","type":"print"},{"value":"1536-0229","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,17]]},"assertion":[{"value":"2026-03-09","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-29","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}